Pro-neuropeptide Y as a circulating biomarker for poor prognosis in prostate cancer.

Sci Rep · 2026 · PMC13291266 · PMID 42337319

Europe PMC DOI

hedged sentence

0.0700

closest p · 1.4× alpha

0.0700

boldest claim

The sentences

showed a trendp = 0.070so close (0.05 < p ≤ 0.1)

Patients in risk group 5 (M1 disease or PSA > 100 μg/l) showed a trend toward higher pro-NPY levels compared with all other risk groups combined (median 0.145 vs. 0.0965 ng/ml, p = 0.070) (Fig. 1 B).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.